News & Views
Scientists test drug to dampen involuntary movements
Apr 13 2011
Revealed at the annual meeting of the American Academy of Neurology, the study was written and conducted by Dr Ravi Anand, a consultant with Newron Pharmaceuticals in Italy.
The research spanned two years and was carried out with patients in the mid-to-late stages of the disease.
Of the 669 people taking part in the trial, some were given the new treatment safinamide and others took a placebo in order to ascertain the drug's effectiveness.
The safinamide was used in addition to levodopa and other dopaminergic treatments.
Showing that patients who took 100 milligrams of the new drug reduced movement issues by 24 per cent in those who scored four or higher on the scale prior to the start of the treatment, the tests demonstrated the drug had less impact at 50 milligrams.
"These results are an important step forward in understanding how safinamide impacts patients with severe Parkinson's disease," commented Dr Anand.
The American Academy of Neurology has over 22,000 members and its annual meeting took place in Honolulu on April 9th.
Digital Edition
ILM 49.5 July
July 2024
Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...
View all digital editions
Events
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia
Jul 31 2024 Chengdu, China
ACS National Meeting - Fall 2024
Aug 18 2024 Denver, CO, USA
Aug 25 2024 Copenhagen, Denmark